Mucopolysaccharidosis Type Iva

• FDA approval · 2024-09-12
  FDA Approved: NAGLAZYME — Supplemental Application (BioMarin Pharmaceutical Inc.)

  FDA approved a supplemental application for NAGLAZYME (galsulfase) from BioMarin Pharmaceutical, expanding/adjusting its approved labeling.

• FDA approval · 2014-02-14
  FDA Approved: VIMIZIM — Original Application (BioMarin Pharmaceutical Inc.)

  FDA approves BioMarin's Vimizim (elosulfase alfa) under an Original Biologics License Application for the treatment of Morquio A syndrome (M…